Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05963347
Other study ID # DZ2022J0003
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 3, 2023
Est. completion date July 31, 2026

Study information

Verified date August 2023
Source Henan Cancer Hospital
Contact Keshu Zhou, Dr.
Phone +86 (0371) 65587513
Email drzhouks77@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date July 31, 2026
Est. primary completion date July 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Participants must sign an informed consent form prior to trial-specific procedures, sampling, and analysis. 2. Participants must be at least 18 years of age (inclusive) at the time of signing the informed consent form. 3. The participant has an ECOG performance status of 0 to 2 and has not deteriorated in the past 2 weeks. 4. Life expectancy = 3 months. 5. Histologically confirmed diagnosis of PTCL and no prior systemic anti-lymphoma therapy; and assessed by a local pathologist according to the 2016 revised World Health Organization Classification of Lymphoid Tumors (Swerdlow SH et al., 2017) as the following subtypes: - peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) - angioimmunoblastic T cell lymphoma (AITL) - follicular T-cell lymphoma (FTCL) - nodular PTCL with follicular helper T-cell phenotype (nodular PTCL with TFH phenotype) - ALK- anaplastic large cell lymphoma (ALK- ALCL) - ALK+ anaplastic large cell lymphoma (ALK + ALCL) - enteropathy-associated T-cell lymphoma (EATL) - monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) - hepatosplenic T-cell lymphoma (HSTCL) - subcutaneous panniculitis-like T-cell lymphoma (SPTCL) 6. Adequate bone marrow reserve and organ system function reserve 7. Left ventricular ejection fraction (LVEF) = 50% as assessed by ECHO. 8. Participants should be able and willing to comply with the study protocol requirement. 9. Adequate birth control measures should be taken during study treatment and the corresponding washout period. Exclusion Criteria: 1. Received any of the following interventions: - Prior therapy for PTCL prior to enrollment, except short-term corticosteroids (duration = 7 days, equivalent prednisone dose = 15 mg/day). - Prior radiation therapy for PTCL except local therapy for individual areas. - Currently receiving other systemic antineoplastic or investigational therapy. - Participants who have received more than 200 mg/m2 doxorubicin or other equivalent doses of anthracycline/anthraquinone (e.g., epirubicin, daunorubicin, mitoxantrone, etc.) cumulatively. - Major surgical procedures (excluding routine lymphoma care programs such as vascular access placement, biopsy, etc.) or significant trauma within 4 weeks prior to the first dose of study treatment, or anticipation of the need for major surgery during the study. - Prior treatment with JAK or STAT3 inhibitors following diagnosis of PTCL. - Live vaccine within 28 days prior to enrollment. - Participants currently receiving (or unable to discontinue for at least 1 week prior to first dose) vitamin K antagonists, antiplatelets, or anticoagulants. - Participants currently receiving (or unable to discontinue for at least 1 week prior to receiving the first dose) medications or herbal supplements known to be highly potent inhibitors or inducers of CYP3A or sensitive substrates of BCRP or P-gp with a narrow therapeutic index (see Section 6.8). 2. Participants with clinical manifestations or imaging findings suggesting central nervous system or leptomeningeal lymphoma. 3. Participants with severe lung dysfunction, pneumonitis, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any prior history of clinically active interstitial lung disease. 4. Participants with a condition that requires treatment with immunosuppressants, biologics, or nonsteroidal anti-inflammatory drugs (NSAIDs). 5. Participants with active infections 6. Participants with significant cardiac disorder 7. Other malignancies within 3 years before enrollment. However, malignancies, such as uterine and cervical carcinoma in situ, basal or squamous cell carcinoma, and non-melanotic skin cancer, which have been clinically cured after evaluation, may be considered for inclusion after evaluation. 8. Refractory nausea or vomiting that cannot be controlled by supportive therapy, chronic gastrointestinal disease, inability to swallow pharmaceutical agents or previous major bowel resection may affect the adequate absorption of golidocitinib. 9. Female participants who are lactating. 10. Participants with a history of hypersensitivity against the active ingredients or excipients of golidocitinib or against similar chemical structures or drugs of the same class. Contraindication to any agent in the CHOP chemotherapy regimen. 11. Participants with any severe or poorly controlled systemic disease, such as poorly controlled hypertension or active bleeding constitution, as judged by the investigator or other evidence. 12. Participants with an intercurrent illness that, in the opinion of the investigator, may jeopardize compliance with the protocol, including any significant medical condition, laboratory abnormality, or psychiatric disorder. 13. Participants with psychological, familial, social, or geographical conditions that preclude compliance with the program. Any condition that would confound the ability to interpret study data. 14. Participating in study planning and implementation.

Study Design


Intervention

Drug:
Golidocitinib
Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.
CHOP Regimen
CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.

Locations

Country Name City State
China Henan Cancer Hospital Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] TEAE, lab test From first dose till 28 days post the last dose
Secondary Complete Response Rate Complete response rate by Cycle 3 and Cycle 6 assessed by investigator per Lugano 2014 criteria From date of enrollment (first dose) until the end of induction therapy completed (~ 18 weeks)
Secondary Objective Response Rate Objective response rate by Cycle 3 and Cycle 6 assessed by investigator per Lugano 2014 criteria. From date of enrollment (first dose) until the end of induction therapy completed (~ 18 weeks)
Secondary Progression Free Survival Objective response rate by Cycle 3 and Cycle 6 assessed by investigator per Lugano 2014 criteria. From date of enrollment (first dose) until documented disease progression or death of any reason (up 2 year)
Secondary Duration of Response Duration of response assessed by investigator per Lugano 2014 criteria from first documented response till disease progression or death of any reason (up to 2 years)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05559008 - A Umbrella Study in R/R PTCL Guided by Molecular Subtypes Phase 1/Phase 2
Recruiting NCT06083701 - Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study Phase 1/Phase 2
Not yet recruiting NCT02856997 - Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04083495 - CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma Phase 2
Not yet recruiting NCT05979792 - Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma Early Phase 1
Recruiting NCT04984837 - Study of Lacutamab in Peripheral T-cell Lymphoma Phase 2
Recruiting NCT06072131 - To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Phase 3
Completed NCT01716806 - A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Phase 2
Terminated NCT03947255 - A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04028440 - γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Early Phase 1
Not yet recruiting NCT05923502 - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Recruiting NCT05377827 - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Phase 1
Recruiting NCT05883449 - Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL Phase 2
Active, not recruiting NCT03586999 - Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Phase 1/Phase 2
Recruiting NCT04489264 - The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Recruiting NCT06151106 - Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma Phase 2
Recruiting NCT02753543 - Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma Phase 2
Not yet recruiting NCT06089941 - Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas